Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

BACKGROUND: Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal antibody to proprotein convertase subtilisin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lipids Health Dis
Autors principals: Teramoto, Tamio, Kondo, Akira, Kiyosue, Arihiro, Harada-Shiba, Mariko, Ishigaki, Yasushi, Tobita, Kimimasa, Kawabata, Yumiko, Ozaki, Asuka, Baccara-Dinet, Marie T., Sata, Masataka
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5474052/
https://ncbi.nlm.nih.gov/pubmed/28623954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12944-017-0513-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars